Sotera Health reports Q4 adjusted EPS 25c, consensus 22c

Reports Q4 revenue $251.59M, consensus $247.55M. "Our fourth-quarter and full-year 2022 results demonstrate the resilience of our business model," said Chairman and Chief Executive Officer, Michael Petras, Jr. "This marks the 9th consecutive reporting period in which we delivered both top and bottom-line growth. 2022 was challenging as the Company faced uncertainty driven by macroeconomic pressures and geopolitical events. Our team did a great job offsetting inflationary pressures and mitigating supply chain challenges to meet demand and ensure our customers were served with excellence." Petras continued, "We continue to position ourselves for growth through our ongoing capacity expansions as well as executing on our global operational excellence initiatives. Additionally, the EO settlement term sheets reached in January are in the best interests of the Company and its shareholders. We are excited for continued growth in 2023 as we remain focused on our mission of Safeguarding Global Health."